Acura Pharmaceuticals Inc. ACUR, Trading End at $5.77
Acura Pharmaceuticals Inc. ACUR
Acura Pharmaceuticals, Inc. announced that it has submitted a briefing package to the U.S. Food and Drug Administration addressing the issues raised in the FDA's June 30, 2009 Complete Response Letter related to the New Drug Application for Acurox (oxycodone HCl/niacin) Tablets.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to BOTTOM of this page for free stock alerts, or visit our site.
Last Trade: 5.77 Day's Range: N/A - N/A 52wk Range: 0.00 - 9.00 Change: 0.00 (0.00%) Volume: 0 Avg Vol (3m): 56,600 ABOUT Acura Pharmaceuticals Inc.
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and manufacture of Aversion Technology related product candidates. The company’s Aversion Technology acts as a platform for developing multiple opioid analgesic products candidates containing codeine, propoxyphene, morphine, hydrocodone, oxycodone, tramadol, and various other opioid analgesics. Its opioid analgesic products are used to relieve pain, as well as to discourage common methods of pharmaceutical product misuse and abuse, including intravenous injection of dissolved tablets or capsules; nasal snorting of crushed tablets or capsules; and intentional swallowing of excess quantities of tablets or capsules.
About Stock Einstein StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
Thank you for your interest in Findit News. A member of the Findit News team will contact you soon to show you how you can take your marketing to the next level with press releases on Findit.
